“The National Women’s Health Network launched the ‘Pass on the Pink Pill – Or Pass Out’ campaign, to warn women of the marginal benefits and serious side effects of the new ‘pink pill’ as drug sales begin. Flibanserin, branded as Addyi – alleged to boost female libido was recently approved by the FDA and bought by Valeant Pharmaceuticals for $1 billion. Valeant is a pharmaceutical giant known for price gouging and shady business practices. Rather than rely on drug company marketing, NWHN recommends that women educate themselves and pass on the pink pill.”
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.